| Document |
Document Title |
|
WO/2024/104453A1 |
The present disclosure relates to a fused tricyclic compound, a preparation method therefor, and pharmaceutical use thereof. Specifically, the present disclosure relates to a fused tricyclic compound represented by general formula (I), a...
|
|
WO/2024/107711A1 |
The present disclosure provides bifunctional compounds comprising a target protein binding moiety and a E3 ubiquitin ligase binding moiety, and associated methods of use.
|
|
WO/2024/104435A1 |
Disclosed are a tricyclic PI3Kα inhibitor, a preparation method therefor, and pharmaceutical use thereof. Particularly, the present invention relates to a compound represented by general formula (1), a preparation method therefor, and u...
|
|
WO/2024/105410A2 |
There is described a compound comprising a sequence of at least 3 amino acids wherein the sequence of 3 amino acids comprises the sequence Ser-Arg-Ala; and variants and derivatives thereof; provided that the amino acid is not: His-Lys-Se...
|
|
WO/2024/107641A1 |
Provided herein are compositions, systems, kits, and methods for treating a patient with cancer (e.g., Ewing's Sarcoma) by treating the patient with at least one of the following compositions: a) a composition comprising at least a porti...
|
|
WO/2024/106739A1 |
The present invention relates to a composition containing as an active ingredient a compound for the prevention, alleviation, or treatment of glioblastoma as an active ingredient. The compound of chemical formula 1 according to the prese...
|
|
WO/2024/103187A1 |
A new composition of matter composed of engineered sequences for the expression of Fap2-derived polypeptides that provoke immunogenic responses against Fusobacterium spp. is provided. Antibodies and vaccines produced using such sequences...
|
|
WO/2024/106979A1 |
The present invention relates to a piperidine derivative compound and a use thereof. The piperidine derivative compound of the present invention exhibits excellent inhibitory activity against FLT3, and thus can be usefully employed in th...
|
|
WO/2024/103313A1 |
Provided are combinations and therapeutic methods comprising genetically modified macrophages, monocytes or stem cell-derived macrophages/monocytes comprising an immune responsive gene 1(Irg1) gene knockout, mutation, or knockdown, in co...
|
|
WO/2024/108231A1 |
Systems and methods are provided herein for determining areas of low blood flow, low blood perfusion, suboptimal treatment perfusion, and/or likelihood of tumor recurrence. For example patient-specific methods are provided for identifyin...
|
|
WO/2024/104268A1 |
The present invention relates to a co-crystal of elacestrant (hereinafter referred to as "compound (I)") dihydrochloride and a preparation method therefor, a pharmaceutical composition comprising the co-crystal, and a use of the co-cryst...
|
|
WO/2023/244582A9 |
This application relates generally to lung cancer-related biomarkers, such as aggressive lung cancer-related molecules, which can be used to predict clinical outcomes, such as patient overall survival and/or metastasis-free survival, and...
|
|
WO/2024/104443A1 |
A use of an active ingredient that carries out targeted regulation of metabolite expression levels or closes off a binding site of an LKB1 protein and a metabolite for preventing and/or treating an AMPK kinase-mediated metabolic-related ...
|
|
WO/2024/107899A1 |
Provided are methods and dosage regimens for treating cancer using an antibody that specifically binds to human DDR1.
|
|
WO/2024/106448A1 |
The nucleic acid construct according to the present invention has such a structure that a protein can be expressed by the occurrence of at least two times of a recombinant reaction by single-strand annealing (SSA), is useful for the diag...
|
|
WO/2024/107565A1 |
Provided herein are inhibitors of AKT1, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the AKT1 inhibitory compounds for the treatment of disease.
|
|
WO/2024/104455A1 |
A CDK2 inhibitor and a preparation method therefor, and a pharmaceutical composition. The present invention further relates to a use of the compound or the pharmaceutical composition in preparation of drugs for preventing or treating rel...
|
|
WO/2024/107731A2 |
Anti-PD-L1 antibodies and antigen-binding fragments thereof and related compositions useful in any of a variety of therapeutic and diagnostic methods for the treatment of diseases and disorders, such as cancer and chronic viral infections.
|
|
WO/2024/104433A1 |
Provided are use of galectin-1 (Gal-1) as an immune checkpoint in the preparation of a tumor immunotherapy medicament and the medicament, and provided is a new tumor immunotherapy strategy targeting the new immune checkpoint. Lactose and...
|
|
WO/2024/104250A1 |
Provided are a polycyclic compound as a GPR75 activator, a pharmaceutical composition comprising same, and use thereof. Specifically, the present invention relates to a compound having a structure of formula (1) or a pharmaceutically acc...
|
|
WO/2024/107410A1 |
Compositions and methods are provided herein relating to Treg cells modified by introduction of a chimeric antigen receptor (CAR), referred to herein as CAR-Treg cells. Populations of CAR-Treg cells are bimodal with respect to expression...
|
|
WO/2024/103107A1 |
The present disclosure relates generally to fusion proteins comprising a truncated transforming growth factor beta receptor 2 (TGFBRII) and one or more intracellular co-stimulatory domains.
|
|
WO/2024/105049A1 |
Described are combination therapy for the treatment of cancer, particularly soft-tissue sarcoma, comprising lurbinectedin and doxorubicin at low doses.
|
|
WO/2024/107014A1 |
The present disclosure relates to an anti-basal cell adhesion molecule (BCAM) antibody-drug conjugate where the anti-BCAM antibody is conjugated to an antitumor compound via a linker, a pharmaceutical composition comprising the anti-BCAM...
|
|
WO/2024/105159A1 |
The present invention relates to a compound of formula (I) or (II), (I), (II) for use as a medicament in the treatment of cancer.
|
|
WO/2024/104561A1 |
Therapeutic combinations of capivasertib and venetoclax are described. The combinations can be useful in the treatment of B-cell malignancies. In some embodiments, reduced dosing (e.g., reduced frequency and/or reduced amount) of venetoc...
|
|
WO/2024/104384A1 |
Provided herein are an indene compound, e.g., a compound of Formula (I), and a pharmaceutical composition thereof. Also provided herein is a method of their use for treating, preventing, or ameliorating one or more symptoms of a fibrotic...
|
|
WO/2024/107850A1 |
Substituted halo-dehydro-3'-deoxyuracil phosphoramidates and related compounds, pharmaceutical compositions, their use for inhibiting LINE1 reverse transcriptase and/or HERV-K reverse transcriptase activity, and their use in the treatmen...
|
|
WO/2024/105144A1 |
The present invention is directed to (3R)-N-[2-cyano-4-fluoro-3-(3-methyl-4-oxo- quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonami
de or a pharmaceutically acceptable salt thereof, for novel uses in the treatment of locally ad...
|
|
WO/2024/017371A9 |
The present invention relates to a multispecific antibody, such as a bispecific antibody, comprising a mutated amino acid pair capable of promoting homologous pairing of a heavy chain and a light chain of the multispecific antibody.
|
|
WO/2024/106538A1 |
The present invention provides: a lymphocyte cleansing method that involves cleansing lymphocytes with a bicarbonate ion–containing physiological aqueous solution; a lymphocyte cryopreservation method that involves suspending and freez...
|
|
WO/2024/105193A1 |
The present disclosure relates, inter alia, to biologically active substances extracted from animal tissue or cell culture comprising non- pathologically proliferating cells, which substances simultaneously (i) induce and/or intensify ce...
|
|
WO/2024/061364A9 |
The present invention relates to the technical field of biological medicines, and particularly, to an anti-4-1BB nanobody, a preparation method therefor, and use thereof. A complementary determining region of the anti-4-1BB nanobody comp...
|
|
WO/2024/104364A1 |
The present invention relates to a pan-KRAS inhibitor compound represented by formula (I), a pharmaceutical composition comprising the compound, and use of the compound of formula (I) in preventing and/or treating a cancer, a tumor, an i...
|
|
WO/2024/107624A1 |
The current disclosure relates to animal models, methods for screening and testing of anti-cancer drug candidates, and to methods for treatment, evaluating efficacy of cancer treatment, and selecting patients for cancer therapy.
|
|
WO/2024/105363A1 |
The present invention relates to compounds of formula (I). The compounds may be used to modulate activity of the HPK-1 protein, and thereby treat cancer, viral infection and immune-mediated disorders.
|
|
WO/2024/106939A1 |
The present invention relates to an anti-B7-H3 antibody or an antigen-binding fragment thereof, which binds to a specific epitope located within the amino acid sequence of a domain of B7-H3. The antibody (i) specifically binds to various...
|
|
WO/2024/107661A2 |
RAS proteins are frequently mutated in human cancers. Disclosed herein are compounds that disrupt RAS effectors and inhibits Ras/Raf/MEK/ERK pathway signaling. Further disclosed herein are methods of using compounds in combination with c...
|
|
WO/2024/103161A1 |
Despite significant progresses made in the treatment of cancers with the development of immune checkpoint inhibitors (ICI), several cancers exhibit resistance to these agents. Certain tumors are considered immunologically cold tumors usu...
|
|
WO/2024/104373A1 |
Provided are affinity-maturated single domain anti-PD-L1 antibodies and polypeptides, such as multispecific antibodies and chimeric antigen receptors, that include these single domain antibodies. These antibodies, including their humaniz...
|
|
WO/2024/104282A1 |
A compound as represented by formula (I) and/or a stereoisomer, tautomer or pharmaceutically acceptable salt or solvate of the compound of formula (I), a preparation method therefor, a pharmaceutical composition comprising the compound o...
|
|
WO/2024/105563A1 |
This disclosure relates to compounds of Formula (I), or a pharmaceutically acceptable salt thereof, in which R1, R2, R3, R4, R5, R6, W, X, Y, and q are as defined herein, to pharmaceutical compositions comprising such compounds and salts...
|
|
WO/2024/103251A1 |
The present application relates to an anti-AFP/HLA02 TCR-like antibody and the use thereof. The antibody can specifically bind to a human AFP158-166/HLA-A02*01* complex with a KD value of about 3.1E-09M or less. The present application f...
|
|
WO/2024/105610A1 |
The present invention provides a pharmaceutical combination comprising a WRN inhibitor in combination with at least one additional therapeutically active agent. It also provides a method of treating cancer, involving administering to a s...
|
|
WO/2024/108094A1 |
Methods and compositions are provided for lyophilizing compositions comprising a peptide-decorated lipid.
|
|
WO/2024/105656A1 |
HER receptor derived peptides are provided. Accordingly there is provided a composition of matter comprising a peptide comprising an amino acid sequence of a nuclear localization sequence (NLS) of a HER receptor capable of binding a nucl...
|
|
WO/2024/107434A1 |
The present invention relates to compounds of formula (I) or a salt, stereoisomer, tautomer or N-oxide thereof. Furthermore, the present invention relates to compounds of formula (I), or a salt, stereoisomer, tautomer or N-oxide thereof,...
|
|
WO/2024/105276A1 |
In one aspect, the invention relates to the use of difluoromethylornithine (DFMO) in treatment of cancer. The drug is administered to a patient undergoing a dietary regimen and/or drug treatment that is designed to reduce a plasma level ...
|
|
WO/2024/106501A1 |
[Problem] To provide an oral agent capable of maintaining the health of mammary tissue. [Solution] This agent for maintaining the health of mammary tissue is characterized by containing GABA as an active ingredient. By using GABA in comb...
|
|
WO/2024/106647A1 |
The present invention relates to an anticancer adjuvant containing pentadecanoic acid as an active ingredient, and uses thereof, and, specifically, to: a composition for enhancing anticancer agent sensitivity of anticancer-agent-resistan...
|
